BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
BOSTON SCIENTIFIC CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$45.05+0.66 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $66.44B
- P/E (TTM)
- 18.2
- Dividend yield
- –
BOSTON SCIENTIFIC CORP revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $13.95B | $13.67B | $13.25B | $12.72B | $12.10B | $11.40B | $10.76B | $10.10B | $9.55B | $9.15B | $8.82B | $8.54B | 66.4% | +15.2% |
| MedSurg | $7.05B | $6.95B | $6.82B | $6.64B | $6.39B | $6.16B | $5.99B | $5.82B | $5.68B | $5.55B | $5.42B | $5.28B | 33.6% | +10.3% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Electrophysiology | $3.58B | $3.50B | $3.33B | $3.08B | $2.75B | $2.33B | $1.90B | $1.50B | $1.16B | $923.00M | $800.00M | $727.00M | 17.0% | +30.2% |
| Endoscopy | $3.04B | $2.98B | $2.92B | $2.85B | $2.78B | $2.72B | $2.69B | $2.64B | $2.59B | $2.55B | $2.48B | $2.41B | 14.5% | +9.2% |
| Urology | $2.73B | $2.72B | $2.71B | $2.62B | $2.47B | $2.32B | $2.20B | $2.10B | $2.05B | $2.01B | $1.96B | $1.91B | 13.0% | +10.4% |
| Cardiac Rhythm Management | $2.33B | $2.33B | $2.33B | $2.31B | $2.30B | $2.28B | $2.28B | $2.27B | $2.26B | $2.25B | $2.22B | $2.19B | 11.1% | +1.4% |
| Watchman | $2.06B | $2.04B | $1.96B | $1.84B | $1.70B | $1.60B | $1.52B | $1.45B | $1.39B | $1.33B | $1.27B | $1.21B | 9.8% | +20.9% |
| Neuromodulation | $1.29B | $1.25B | $1.20B | $1.17B | $1.14B | $1.12B | $1.11B | $1.07B | $1.04B | $997.00M | $976.00M | $955.00M | 6.1% | +12.6% |
| Peripheral Interventions [Member] | – | – | – | $2.70B | $2.60B | $2.49B | $2.41B | $2.30B | $2.23B | $2.18B | $2.11B | $2.05B | – | – |
| Cardiology [Member] | – | – | – | $10.01B | $9.50B | $8.90B | $8.34B | $7.80B | $7.32B | $6.97B | $6.71B | $6.49B | – | – |
| Interventional Cardiology & Vascular Therapies | – | – | – | $3.66B | $3.63B | $3.12B | $2.65B | $2.59B | $2.51B | $2.48B | $2.42B | $2.36B | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $13.39B | $13.19B | $12.86B | $12.37B | $11.67B | $10.91B | $10.21B | $9.53B | $9.04B | $8.68B | $8.43B | $8.20B | 63.8% | +14.7% |
| Int'l | $7.61B | $7.43B | $7.21B | $6.98B | $6.82B | $6.64B | $6.54B | $6.38B | $6.19B | $6.03B | $5.82B | $5.62B | 36.2% | +11.5% |
| Emerging Markets | – | – | $2.99B | $2.88B | $2.80B | $2.72B | $2.68B | $2.61B | $2.52B | $2.43B | $2.31B | $2.23B | – | – |
From the segment and revenue-disaggregation notes of Boston Scientific's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.